

# Massive pulmonary embolism – haemodynamically unstable Patients

<b>TARGET AUDIENCE</b>	Secondary care
<b>PATIENT GROUP</b>	Adult patients in acute care setting

## Clinical Guidelines Summary

### Definition of Massive PE


PE associated with a systolic blood pressure <90 mmHg or a drop in systolic blood pressure of  $\geq 40$ mmHg from baseline for a period >15 minutes (not otherwise explained by hypovolaemia, sepsis or new arrhythmia)

### Clinically suspected massive PE:-

- Heparinise with IV Unfractionated heparin bolus (5000 units) then IV infusion (18 units/kg/hour, up to max dose 1800 units/hour), adjusted to maintain APTT ratio of 1.8-2.8
- O<sub>2</sub>
- IV fluids (Plasma-Lyte 148) and inotropic support
- If pregnant, inform on-call obstetric team immediately for consideration of early delivery

Transfer to CCU/ICU/HDU/Resus

Emergency CTPA  
(Cardiac echo if not available)



Lead Author	M Malekian	Date approved	December 2023
Version	2	Review Date	December 2026

## **Thrombolysis in patients who are peri-arrest or arrested**

Massive pulmonary embolism is cause of arrest in 5-13% of patients. Patients with massive pulmonary embolism who progress to cardiac arrest have 65-90% mortality rate.

In some patients there may have not been sufficient time after presentation to perform confirmatory tests before they progress to cardiac arrest. If there is high clinical suspicion of PE, then thrombolytic therapy should be considered and decision to give thrombolytic approved by a senior clinician.

Please note that dose of Alteplase in case of cardiac arrest is different (out with license but total dose the same and in keeping with consensus view) as detailed below;

Alteplase 50mg IV bolus over 2 minutes, then continue CPR for at least 15-30 minutes. If restoration of spontaneous circulation (ROSC) is not achieved, consider repeat dose of 50 mg IV (adjust second dose if weight <65kg) and continuation of CPR. When thrombolytic drugs have been administered, consider continuing CPR attempts for at least 60-90 minutes before termination of resuscitation attempts

<b>Lead Author</b>	<b>M Malekian</b>	<b>Date approved</b>	<b>December 2023</b>
<b>Version</b>	<b>2</b>	<b>Review Date</b>	<b>December 2026</b>

## Appendices

### 1. Governance information for Guidance document

<b>Lead Author(s):</b>	Mehrdad Malekian
<b>Endorsing Body:</b>	ADTC
<b>Version Number:</b>	2
<b>Approval date</b>	December 2023
<b>Review Date:</b>	December 2026
<b>Responsible Person (if different from lead author)</b>	

<b>CONSULTATION AND DISTRIBUTION RECORD</b>	
<b>Contributing Author / Authors</b>	Manish Patel, Raheel Syeed, Julie Cash, Helen Barclay, Mairi McGuire, Annielle Hung, Marion Devers, Calum McGregor
<b>Consultation Process / Stakeholders:</b>	Stake-holders in secondary case as noted above

<b>Lead Author</b>	M Malekian	<b>Date approved</b>	December 2023
<b>Version</b>	2	<b>Review Date</b>	December 2026

<b>Distribution</b>	
---------------------	--

<b>CHANGE RECORD</b>			
<b>Date</b>	<b>Lead Author</b>	<b>Change</b>	<b>Version No.</b>
2017	M Malekian	<i>Original guidance approved</i>	1
			2
			3
			4
			5

<b>Lead Author</b>	M Malekian	<b>Date approved</b>	December 2023
<b>Version</b>	2	<b>Review Date</b>	December 2026